Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer (original) (raw)
Teniposide (VM26) disposition in children with leukemia
Gary Dahl
Cancer research, 1984
View PDFchevron_right
Teniposide ( VM 26 ) Disposition in Children with Leukemia 1
Joseph Sinkule
2006
View PDFchevron_right
Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors
Paul Hutson
Cancer research, 1984
View PDFchevron_right
Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation
Stephen Lowis
Cancer research, 1993
View PDFchevron_right
Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide
Shaokun Pang, Naiyu Zheng
Clinical Cancer Research, 2004
View PDFchevron_right
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients
Marc Sunderland
Cancer research, 1990
View PDFchevron_right
957 Bioavailability and pharmacokinetics of oral etoposide (VP16) in elderly patients
Antonio Lucenti
European Journal of Cancer, 1995
View PDFchevron_right
Pharmacokinetic Study of High Dose Etoposide Infusion in Patients with Small Cell Lung Cancer
Hilmar Warenius
Acta Oncologica, 1988
View PDFchevron_right
The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide
Atholl Johnston
British journal of cancer, 1985
View PDFchevron_right
Bioavailability of Etoposide after Oral Administration of the Solution Marketed for Intravenous Use
Jaime de la Garza Salazar, Gilberto Castañeda-Hernández
Archives of Medical Research, 1999
View PDFchevron_right
Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer
Joseph Sinkule
PubMed, 1987
View PDFchevron_right
Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia
Pierre Lafolie
Medical oncology and tumor pharmacotherapy, 1989
View PDFchevron_right
Drug administration and blood sampling for pharmacokinetic studies in pediatric cancer patients
Carina Ritzmo
2009
View PDFchevron_right
A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children
Stephen Lowis
British journal of cancer, 1998
View PDFchevron_right
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer
Peter Steinherz
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters
Huw Thomas
Journal of Pharmacokinetics and Biopharmaceutics, 1996
View PDFchevron_right
Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy
MICHAEL COLE
2011
View PDFchevron_right
Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer
Harvey Niell
Cancer Chemotherapy and Pharmacology, 1992
View PDFchevron_right
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia
Norman Lacayo
Leukemia, 2002
View PDFchevron_right
Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia
Pierre Lafolie
European journal of clinical pharmacology, 1991
View PDFchevron_right
Cyclophosphamide pharmacokinetics in children
MICHAEL COLE
British Journal of Clinical Pharmacology, 1996
View PDFchevron_right
Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours
P. Berthaud
European Journal of Cancer, 2007
View PDFchevron_right
Etoposide for the treatment of paediatric tumours: What is the best way to give it?
S. Lowis
European Journal of Cancer, 1996
View PDFchevron_right
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect
Jean-marc Tréluyer, Saik Urien
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor
Teresa Dalla Costa
Pharmaceutical research, 2016
View PDFchevron_right
Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors
Garrett Brodeur
Investigational New Drugs, 1988
View PDFchevron_right
Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non-Hodgkin’s Lymphoma
Mohamadi Sarkar
Pharmacotherapy, 1999
View PDFchevron_right
Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies
Alain Gouyette
European Journal of Cancer and Clinical Oncology, 1987
View PDFchevron_right